投资决策
伊利股份 (600887.SS)
潜在回报: 19%
布局有利形势 - 买入，并加入强力买入名单（摘要）
建议理由
个月里加紧了推广, 凭借主要高端产品扩大其市场领先地位。我们预计公司销售额
在经历了五个表现平平的季度后,将从 2017 年二季度开始以接近两位数的速度同
比增长; 2) 2017 年下半年里, 我们预计国内供应削减以及进口下降将推动原奶价
格进入上行周期。由于竞争相应放缓，我们认为 2017 年伊利将能够降低其整体广
告促销开支率,抵消成本压力。因此我们目前预计 2016-18 年营业利润和每股盈
投资摘要指标的全面描述请参见本
报告的信息披露部分。
的上行空间。
推动因素
1) 销售额从 2017 年二季度开始加速增长: 我们预计 2017 年二/三季度销售额增速
为 9%, 而过去五个季度的增速处于+/-3%。推动销售额加速增长的主要因素在于
常温酸奶/高档常温奶进一步强劲增长以及液态奶最近促销力度加大。婴幼儿配方
奶业务也在逐步复苏。2) 控制广告促销开支以及 2017 年下半年的原奶价格上行周
期将抵消毛利率压力: 我们估测 2017 年伊利的广告促销开支率将同比下降 50 个
基点。考虑到国内供应削减（因为在当前奶价下，小规模奶农退出无利可图的生
产)以及进口下降(因为全球/中国奶价缺口收窄),我们认为2017年下半年中国
原奶价格将复苏。在我们看来，这将缓解竞争压力并且下游领先企业将收益最大。
3) 收购并购:由于伊利将实现其 2020 年人民币 1000 亿元的销售目标,我们预计
乳业业务可能成为潜在选项，从而令伊利当前的产品结构多元化。
股价走势图
3,600
3,500
3,400
22.40 元上调至 22.90 元,基于 2018 年预期 EV/GCI vs. CROCI/WACC（行业现
3,300
3,200
主要风险
3,100
液态奶销售放缓，毛利率下降，收购并购带来摊薄影响。
3,000
Nay-16
Aug-16
Dec-16
Mar-17
一伊利股份 (左軸)
一 - 沪深300指数 (右軸)
所属投资名单
亚太买入名单
亚太强力买入名单
行业评级: 中性
存在业务关系，并且继续寻求发展这些关系。因此，投资者应当考虑到本公司可能存在可能影响本报告客观性的利益冲突，不应视本报告
信息披露附录，或请与您的投资代表联系。
投资研究
2017年5月25日
伊利股份 (600887.SS)
伊利股份:
财务数据概要
对此报告有贡献的人员
廖绪发, CFA
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
Faster sales from 2Q17; further market share gains
Following five quarters of slower/flattish sales growth, we now expect acceleration to a high
single-digit yoy rate from 2Q17 and sustained growth of 7-8% over the next two years.
Continued liquid milk market share gains from best-selling products, increased promotional
intensity and gradual recovery of the infant milk formula (IMF) market will be the main drivers of
faster growth, in our view.
Yili quarterly sales
Source: Company data, Goldman Sachs Global Investment Research.
Source: Nielsen.
Increasing promotional activity to drive sales
We have seen in the past few months that Yili has started to increase promotional intensity,
especially in key product SKUs such as Satine, its premium UHT long-life product.
The data we track from Carrefour supermarket in Shanghai indicate Yili has offered on average
17% price discounts for Satine, vs. almost no price discount for Mengniu's Milk Deluxe in 1Q17.
The discount for Satine is larger than in 2H16 (-5% on average) but similar to 1H16's level. We
observe similar discounting for Yili's UHT yogurt products as competition remains intense in that
category.
We believe this increased promotion level is consistent with the company's strategy for 2017: to
focus more on sales growth and target an 8% increase in organic sales for 2017. We expect Yili's
sales to start benefiting from this strategic move from 2Q17 and we see both leaders Yili and
Mengniu gaining market share from the small regional players.
2017年5月25日
伊利股份 (600887.SS)
Exhibit 4: UHT yogurt category competition is still
Price discounts - Premium UHT
Price discounts - UHT yogurt
UHTYoghurt Discount from Original price
Source: Carrefour Shanghai.
Source: Carrefour Shanghai.
Premium UHT milk and yogurt are key growth drivers
As illustrated in Exhibits 5 and 6, we expect UHT/chilled yogurt and premium UHT milk to
contribute the most to Yili's topline, driving the acceleration for 2017.
We see the UHT yogurt market continuing to grow at a high-teens yoy rate in 2017 and look for
Yili to extend its leadership with a 45% market share (vs less than 30% in 2015). We forecast that
Yili's Ambrosial drinkable yoghurt product will record Rmb10bn sales in 2017 (+40% yoy), driven
by active marketing campaigns and more product package/taste SKUs.
Source: Company data, Goldman Sachs Global Investment Research
Source: Company data, Goldman Sachs Global Investment Research
New products: Yili has recently launched a new bottle-shaped package for Ambrosial. Also,
earlier this year the company launched a premium chilled yogurt product Pureday, priced at
Rmb9.2/110g. These products cater increasingly to urban consumers who are willing to pay extra
for healthy and tasty products. New products contributed about 20% of sales in 2016 and Yili is
targeting another 15-20% contribution from new products again in 2017.
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
Chilled yogurt product
Source: Company data.
Source: Company data.
IMF: gradual recovery in 2H17, expect 8% Yili IMF growth
IMF industry sales turned downward yoy in 2016 on a 3% drop in ASP vs. a 2% rise in volume,
but Nielsen data indicate a gradual recovery in 1Q17, with 5% growth from ASP and 2% from
volume. With a more favorable demographic trend in 2017 (2016 newborns grew over 10% yoy),
we expect stronger demand for stage 1-2 products in 2017. Further, we believe stringent
regulations, for example on limiting the number of series/formulas per company, will favor larger
companies going into 2H17. (Smaller companies typically will offer more series to attract
consumers, and their formulas are also less likely to register successfully.)
Our latest price check of mom & baby stores and distributors still indicates a competitive industry
for 1H17. However, with smaller brands continuing to exit the market, and with the first batch of
registered brands (those for which formulas are registered with the China regulatory authorities)
likely to be announced in 3Q17, we expect distributors will become more confident to take on
inventory in 2H17.
The latest Nielsen data show that Yili maintains a stable market share in offline channels (Exhibit
10), and we expect 8% IMF sales growth in 2017 vs. a 15% decline in 2016.
Source: Company data, Nielsen, Euromonitor.
Source: Nielsen.
2017年5月25日
伊利股份 (600887.SS)
Product mix, lower A&P ratio to offset gross margin pressure
We believe the market may have concerns about margin pressure on Yili in 2017. In 1Q17, Yili's
GPM dropped by 400bps yoy due to rising packaging material costs, while recently added price
promotions could also negatively impact GPM for the rest of year.
However, we believe a better product mix and declining A&P ratio should largely offset
the cost pressure.
1) We expect steady 4-5% ASP growth from product mix over 2017-2018E (6.2% in 2016)
on stronger growth in flagship products.
2) We believe Yili will start to lower its A&P expenses ratio in 2017, in contrast to the sharp
increase over the past three years. In 1Q Yili recorded 400bps yoy lower selling expenses and we
expect the full-year SG&A ratio to come in 80bps lower, mainly driven by A&P spending restraint.
Yili's direct peer Mengniu has also commented at result briefings on containing A&P spending
and expects a flattish ratio in 2017.
3) Cost pressures more contained: The main rising cost for Yili is paper products, which
account for less than 5% of total COGS in 2016. The major cost component, raw milk, is likely to
stay at a flat level yoy for 2017 as a whole, in our view. In 1H17 we see a continued yoy decline in
raw milk cost, while we expect a gradual increase starting from 2H17.
Hence, we expect Yili's gross margin minus selling expenses (i.e. OPM) to remain stable for full-
year 2017.
Source: Company data, Goldman Sachs Global Investment Research
Source: Company data, Goldman Sachs Global Investment Research
2017年5月25日
伊利股份 (600887.SS)
partially offsetting the higher cost
Yili per liter profit breakdown
Source: Company data, Goldman Sachs Global Investment Research
Source: Company data, Goldman Sachs Global Investment Research
Exhibit 16: ..and thus we see a stable OPM trend in 2017-
18E
Gross profits after selling expenses vs milk cost
Source: Company data, Goldman Sachs Global Investment Research
Source: Company data, Goldman Sachs Global Investment Research
Improved balance of milk supply/demand in 2H17 likely to drive milk price uptrend and
ease competition
China milk production has continued to shrink since early 2016. The latest Mar-Apr 2017 data
indicate milk supply fell back into negative territory after 1Q16's increase (Exhibit 17). The decline
has been driven by smaller farmers exiting production due to current milk prices not making profit
for them.
Although the China raw milk price has remained at a weak level over the past 3 months, we
highlight that the gap between China and global milk prices has more or less disappeared (China
landed cost basis) and hence we expect a continued decline in milk powder imports for the rest of
We now expect the China raw milk price to bottom out and recover gradually in 2H17. This should
reflect balancing supply/demand and less competition/inventory dumping in the market in 2H17.
We believe that industry leaders will benefit most from a recovery in the supply/demand
balance given that an increase in cost will reduce the incentive of smaller players to maintain
2017年5月25日
伊利股份 (600887.SS)
price competition in order to clear out inventory or gain market share. Historically, we also see a
broad positive correlation for Yili's stock price vs. milk price.
Monthly raw milk production
Source: Ministry of Agriculture of China
Source: China Dairy Industry Association
China raw milk vs. WMP prices
Yili stock price vs. milk price
Source: hesitan.com, Bloomberg, Datastream.
Source: Bloomberg, Datastream.
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
M&A a long term growth engine: 2020 sales target Rmb100bn
In its 1Q results briefing, Yili reiterated its 2020 sales target of Rmb100bn in 2017. This implies a
roughly Rmb20bn gap versus our expectation for organic group sales of Rmb80bn in 2020E.
Accordingly, we believe inorganic M&A will be an important path of growth over the next three
years. Yili has taken a prudent approach to M&A in the past and recently canceled the proposed
acquisition of Shengmu as both parties mutually agreed not to proceed. Going forward, we expect
the premium, overseas brands could be Yili's M&A priority, given it can complement Yili's current
product portfolio and extend the premium positioning.
The media (including Bloomberg on May 10, 2017) has recently reported Yili's intention to bid for
US organic yogurt brand Stonyfield. While we don't take a view of the accuracy of these reports,
we believe that Yili could potentially extend its market leadership if it were to introduce a US
brand into China. We believe foreign premium brands have potential to be successful in China,
given past precedents such as Meiji, Danone, and Mead Johnson.
Sufficient cash: Yili had a net cash position of Rmb14bn as of end-2016, and we see it
continuing to increase its cash position over the next few years, driven by a stable margin and
limited capex needs.
Exhibit 22: While Yili's net cash position is sufficient for
potential M&A
Group sales and YoY
Net cash position
Source: Company data, Goldman Sachs Global Investment Research
Source: Company data, Goldman Sachs Global Investment Research
2017年5月25日
伊利股份 (600887.SS)
Best risk-reward among staples: 16% OP CAGR, 24% ROE, 17X P/E
Reflecting sales acceleration and better margin outlook, we raise our 2018-20E EPS by up to 3%,
and with this lift our 12-month target price to Rmb22.90, from Rmb22.40. Yili is now trading at
18X 12m fwd P/E, lower than its 10-year historical average of 21X, even after
outperforming the market (CSI300) since January 2016 by c.26%. We continue to value Yili using
2018E EV/GCI vs CROCI/WACC, applying a 10% premium to reflect higher returns and growth
profile. We believe cash returns have become an increasingly important factor for investors given
slower growth in the dairy sector. Our 12-month target price implies a 2018E P/E of 20X, below its
historical average of 21X, and offers return potential of 21%, highest in our sector coverage. We
reiterate our Buy rating, adding the shares to our Conviction List as our top pick in
the sector.
and EV/GCI
Yili P/E chart
TP calculation (priced as of May 24 close)
Source: Goldman Sachs Global Investment Research
Source: Company data, Goldman Sachs Global Investment Research.
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
Note: Based on May 24, 2017 closing prices. Target prices are on a 12-month timeframe. NC = Not Covered. * denotes stock is on our regional Conviction List.
Figures for Not Covered companies are based on Bloomberg consensus forecasts.
Source: Bloomberg, Gao Hua Securities Research, Goldman Sachs Global Investment Research
Key risks: Slower liquid milk sales, lower margin from rising cost
and competition, dilutive M&A
We see three key risks to our investment thesis, detailed below.
Slower liquid milk sales: The company could see slower basic UHT milk and chilled yogurt
growth from weaker-than-expected demand. More proactive attempts to gain market share by
peers could also impact sales growth potential.
Lower margin from rising cost and competition: Commodity costs including paper, sugar
and milk costs could move adversely, affecting Yili's margin. Also higher pricing competition from
peers and import players could impact Yili's GPM and result in higher A&P spending than we
forecast.
Dilutive M&A: Yili is currently seeking potential M&A opportunities. Depending on the price paid
and/or performance of any potential acquisition, this could impact Yili's high ROE or EPS
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
Yili Industrial Group (600887.SS)
Rmb millions
Source: Company data, Goldman Sachs Global Investment Research
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
\textit{Gao Hua Securities acknowledges the role of Lincoln Kong, CFA and Yuqing Li of Goldman}
Sachs in the preparation of this product.
2017年5月25日
伊利股份 (600887.SS)
信息披露附录
本人，廖绪发, CFA，在此申明，本报告所表述的所有观点准确反映了本人对上述公司或其证券的个人看法。此外，本人薪金的任何部分不曾与，不与，也将不
会与本报告中的具体推荐意见或观点直接或间接相关。
投资摘要
投资摘要部分通过将一只股票的主要指标与其行业和市场相比较来评价该股的投资环境。所描述的四个主要指标包括增长、回报、估值倍数和波动性。增长、
回报和估值倍数都是运用数种方法综合计算而成，以确定该股在地区研究行业内所处的百分位排名。
每项指标的准确计算方式可能随着财务年度、行业和所属地区的不同而有所变化,但标准方法如下:
增长是下一年预测与当前年度预测的综合比较，如每股盈利、EBITDA 和收入等。 回报是各项资本回报指标一年预测的加总，如 CROCI、平均运用资本回报率
和净资产回报率。 估值倍数根据一年预期估值比率综合计算，如市盈率、股息收益率、EV/FCF、EV/EBITDA、EV/DACF、市净率。 波动性根据 12 个月的历史
波动性计算并经股息调整。
Quantum
Quantum 是提供具体财务报表数据历史、预测和比率的高盛专有数据库，它可以用于对单一公司的深入分析，或在不同行业和市场的公司之间进行比较。
GS SUSTAIN
GS SUSTAIN 是侧重于长期做多建议的相对稳定的全球投资策略。GS SUSTAIN 关注名单涵盖了我们认为相对于全球同业具有持续竞争优势和出色的资本回
报、因而有望在长期内表现出色的行业领军企业。我们对领军企业的筛选基于对以下三方面的量化分析：现金投资的现金回报、行业地位和管理水平（公司管
理层对行业面临的环境、社会和企业治理方面管理的有效性）。
信息披露
相关的股票研究范围
廖绪发, CFA: A股传媒、A股耐用消费品、A股食品饮料、中国消费品。
A 股耐用消费品:格力电器、美的集团、青岛海尔。
A 股食品饮料:古井贡酒、洋河股份、贵州茅台、泸州老窖、青青稞酒、山西汾酒、青岛啤酒(A)、五粮液。
A 股传媒：奥飞娱乐、光线传媒、歌华有线、华录百纳、蓝色光标、中南传媒、分众传媒、省广股份、华谊兄弟、IMAX 中国、凤凰传媒、东方明珠、掌趣科
技、万达电影、华策影视。
中国消费品: 合生元、光明乳业、现代牧业、华润创业、蒙牛乳业、康师傅控股、青岛啤酒(H)、统一企业、中国旺旺、万洲国际、伊利股份。
与公司有关的法定披露
的关系。
没有对下述公司的具体信息披露: 伊利股份 (Rmb19.31)
公司评级、研究行业及评级和相关定义
定。任何未获得买入或卖出评级且拥有活跃评级（即不属于暂停评级、暂无评级、暂停研究或没有研究的股票）的股票均被视为中性评级。每个地区投资评估
出评级的分布可能根据地区投资评估委员会的决定而有所不同。此外，每个地区投资评估委员会管理着地区强力买入或卖出名单，该名单以总体潜在回报规模
了改变。
的其中一项代表其根据行业历史基本面及 / 或估值对研究对象的投资前景的看法。 具吸引力(A): 未来 12 个月内投资前景优于研究范围的历史基本面及 / 或估
值。中性(N): 未来 12 个月内投资前景相对研究范围的历史基本面及 / 或估值持平。 谨慎(C): 未来 12 个月内投资前景劣于研究范围的历史基本面及 / 或估
暂停评级(RS)：由于缺乏足够的基础去确定投资评级或价格目标，或在发表报告方面存在法律、监管或政策的限制，我们已经暂停对这种股票给予投资评级和价
格目标。此前对这种股票作出的投资评级和价格目标(如有的话)将不再有效，因此投资者不应依赖该等资料。 暂停研究(CS): 我们已经暂停对该公司的研究。
没有研究(NC): 我们没有对该公司进行研究。 不存在或不适用(NA): 此资料不存在或不适用。 无意义(NM): 此资料无意义, 因此不包括在报告内。
一般披露
本报告在中国由高华证券分发。高华证券具备证券投资咨询业务资格。
本研究报告仅供我们的客户使用。除了与高盛相关的披露，本研究报告是基于我们认为可靠的目前已公开的信息，但我们不保证该信息的准确性和完整性，客
户也不应该依赖该信息是准确和完整的。报告中的信息、观点、估算和预测均截至报告的发表日，且可能在不事先通知的情况下进行调整。我们会适时地更新
全球投资研究
2017年5月25日
伊利股份 (600887.SS)
高盛高华为高华证券的关联机构，从事投资银行业务。高华证券、高盛高华及它们的关联机构与本报告中涉及的大部分公司保持着投资银行业务和其它业务关
我们的销售人员、交易员和其它专业人员可能会向我们的客户及自营交易部提供与本研究报告中的观点截然相反的口头或书面市场评论或交易策略。我们的资
产管理部门、自营交易部和投资业务部可能会做出与本报告的建议或表达的意见不一致的投资决策。
本评级，此类评级反映了某只股票相对于报告中描述的研究范围内股票的回报潜力。
任上述证券或衍生工具的交易对手，或买卖上述证券或衍生工具。
在高盛组织的会议上的第三方演讲嘉宾（包括高华证券或高盛其它部门人员）的观点不一定反映全球投资研究部的观点，也并非高华证券或高盛的正式观点。
在任何要约出售股票或征求购买股票要约的行为为非法的地区，本报告不构成该等出售要约或征求购买要约。本报告不构成个人投资建议，也没有考虑到个别
客户特殊的投资目标、财务状况或需求。客户应考虑本报告中的任何意见或建议是否符合其特定状况，以及(若有必要)寻求专家的意见，包括税务意见。本报告
中提及的投资价格和价值以及这些投资带来的收入可能会波动。过去的表现并不代表未来的表现，未来的回报也无法保证，投资者可能会损失本金。
某些交易，包括牵涉期货、期权和其它衍生工具的交易，有很大的风险，因此并不适合所有投资者。外汇汇率波动有可能对某些投资的价值或价格或来自这一
投资的收入产生不良影响。
策略结构产品，例如，期权差价结构产品，其交易成本可能较高。与交易相关的文件将根据要求提供。
所有研究报告均以电子出版物的形式刊登在高华客户网上并向所有客户同步提供。高华未授权任何第三方整合者转发其研究报告。有关某特定证券的研究报
告、模型或其它数据,请联络您的销售代表。
全球投资研究